Michael Naso

Michael Naso is Vice President of Cell Engineering at Century Therapeutics, where he leads early discovery efforts to identify engineered cell therapy products for clinical development. Michael was a Director of Cell and Gene Therapy at Janssen Research and Development, leading Janssen’s first gene and cell therapy discovery group. In that role, he initiated Janssens first gene therapy programs utilizing rAAV technology and their first engineered cell therapy efforts toward an allogeneic, off-the-shelf platform. His time in that role led to the identification of novel tumor targeting technologies and engineered cell therapy platforms. While at Janssen and Centocor, he also played important discovery roles bringing numerous product candidates into early development and was part of the discovery teams that launched Remicade, Stelara, Simponi and Tremfya. Michael holds a Ph.D from Thomas Jefferson University in Biochemistry and Molecular Biology.